A GROUP OF MU RESEARCHERS USE CK2 PROTEIN FOR THE TREATING CHRONIC LYMPHOYTIC LEUKEMIA

A research team, led by Dr. Sulaiman Al-Saqaabi - Associate Professor in the Department of Medical Laboratory Sciences, College of Applied Medical Sciences, used advanced techniques in bioinformatics and computational biology to search for naturally sourced compounds targeting the CK2 protein for the treatment of chronic lymphocytic leukemia. The research results indicated that the CK2 protein plays a significant role in the aggressiveness of chronic lymphocytic leukemia, making CK2 a therapeutic target in this disease among thousands of natural compounds. The compound Butyl Xanalterate also showed a high potential to bind and inhibit the activity of the CK2 protein, thus inhibiting the growth and proliferation of cancerous blood cells.

The research was published in the scientific journal "Nature Scientific Reports," which is a journal indexed in the science network and has an impact factor.

This research is conducted by the Health Research Center, and was funded by the Deanship of Scientific Research.